Western pharma is paying billions to license drugs it did not invent. China is collecting.
The numbers behind that sentence are stark. Out-licensing deals worth a combined $137.7 billion were signed by Chinese biotech companies in 2025, according to Pharmcube data cited by Reuters — a tenfold increase from $13.9 billion in 2021. In the first few weeks of 2026, the average deal size for China-origin licensing agreements reached $1.3 billion, up 76% from the prior year. The average upfront fee paid to Chinese firms — the cash handed over before a single milestone is hit — has doubled to $77.7 million.
This is not a trade pattern finding its natural level. It is a structural inversion, and it happened faster than most people in the industry expected.
Five years ago, Chinese biotech companies were licensing Western drugs for their domestic market. Now they are originating molecules that AstraZeneca, GSK, AbbVie, and Bristol Myers Squibb are paying $1 billion, $5 billion, $18 billion to access. The pipeline replenishment story that every major Western pharma CEO has told for a decade has quietly become: license from China.
The deals that drove the jump illustrate the scale. AstraZeneca signed a deal worth up to $18.5 billion with CSPC Pharmaceutical Group for a weight-loss drug, according to Reuters. GSK committed up to $12 billion-plus to Hengrui Pharma, handing over $500 million upfront alone for rights to 12 drug candidates spanning respiratory disease, immunology, and oncology. AbbVie paid up to $5.6 billion to RemeGen for an antibody-drug conjugate, or ADC, platform in early 2026. The upfront checks being written to Chinese counterparties are now measured in hundreds of millions of dollars before a Phase II readout has confirmed the drug works.
"Among all the licensing deals we track in the DealForma database, specifically in-licenses by large-cap pharma companies with at least $50 million upfront, 38% originated from China, accounting for 30% of their total global licensing upfront payments," Chris Dokomajilar, founder and CEO of deal-tracking firm DealForma, told Nature Reviews Drug Discovery. That 38% figure is the one to sit with. Five years ago, it was effectively zero.
What is driving the shift
The mechanics are not complicated. Western pharma companies face what Bank of America analyst Tom Barsha calls a "patent cliff" — more than $200 billion in branded drug revenue at risk of generic competition by 2030. Developing drugs from scratch is slow and expensive. Licensing a drug that has already cleared early clinical trials is faster and, in theory, less risky. And China has spent the past decade building a biotech industry that runs clinical trials quickly and cheaply while also producing genuinely novel science.
Tony Ren, head of Asia healthcare research at Macquarie Capital, told Reuters that global pharmaceutical companies are increasingly viewing China as an integral part of their R&D infrastructure. "Many MNCs are considering China as an integral part of their global R&D infrastructure," Ren said.
The therapeutic areas are telling. China now accounts for nearly 90% of all global antibody-drug conjugate licensing activity, according to Vision Lifesciences — an ADC is essentially an antibody engineered to carry a chemotherapy payload directly into cancer cells, sparing healthy tissue. But the dominance extends beyond cancer drugs. China-based companies are also the primary source for next-generation bispecific antibodies and for GLP-1 obesity candidates competing directly with Novo Nordisk and Eli Lilly.
The deal structure tells the story too
The numbers that matter in licensing deals are not the headline totals — those include milestones that may never be hit. The number that matters is the upfront payment, because that is real money changing hands today. In 2026, upfront fees for China licensing deals have averaged around 7% of total deal value, according to Vision Lifesciences. That sounds small until you do the math: $500 million upfront on a $12 billion deal is not hypothetical. It is a wire transfer that cleared.
The implications for where drugs come from
Here is the structural question that the deal data raises and does not fully answer. If Chinese companies are originating the molecules that Western pharma commercializes, what happens to the pricing power that pharma has historically derived from patent exclusivity?
Pharma's traditional model is simple: own the science, own the patent, own the pricing. License it from someone else, and you are renting. The IRA has already compressed the pricing window for drugs covered by Medicare negotiation. If the underlying molecule originates in China, and that origination point keeps moving earlier in the development cycle, the structural dependency becomes harder to unwind.
Pharma executives would push back on this framing. China's strength, they would argue, is in chemistry and clinical execution, not in originating the fundamental biology. Western companies still own the commercialization infrastructure, the regulatory relationships, and the global sales networks. The molecules flow east to west; the money flows west to east. The dependency is transactional, not structural.
Dokomajilar's data complicates that reassurance. Among deals above $50 million upfront, one out of every three dollars paid by large Western pharma to a licensing partner now goes to a Chinese company, according to TechLifeSci's analysis of DealForma data. In 2020, there was one such deal. In 2025, there were eighteen. The concentration is not hypothetical. It is in the wire transfers.
The BIOSECURE Act's limited bite
The US BIOSECURE Act, which restricts federal contractors from using equipment from certain Chinese genomics and biotech companies, has not meaningfully slowed the deal flow. Deal structures have adapted: companies are writing compliance requirements into agreements that move manufacturing outside sanctioned Chinese firms. BD executives are incorporating BIOSECURE compliance into due diligence rather than avoiding China-origin assets entirely, Reuters reported.
"Price is generally not the top of mind when it comes to pharma deals," Ren told Reuters. The pipeline pressure from the patent cliff is overriding whatever geopolitical friction exists.
What happens next is not mysterious. The clinical trial pipeline that Chinese companies have been building for the past decade is deep and getting deeper. The deals signed in 2025 and early 2026 will produce Phase II and Phase III data readouts over the next three to five years. The question is whether those data confirm that China-originated molecules can compete clinically — and whether the dependency deepens before anyone in the West calls it what it is.
The structural shift is real. Whether it constitutes a strategic vulnerability or simply a new way of distributing R&D risk across geographies depends on who you ask — and how much of their pipeline they have riding on the answer.
